Acadia Healthcare Company, Inc.

Acadia Healthcare Company, Inc. (ACHC) operates in the behavioral healthcare industry, providing services for high-acuity and complex-needs patient populations across the United States and Puerto Rico. The company's business model is centered on generating revenue through various behavioral healthcare services, with a mix of recurring and transactional income from diverse customer segments. ACHC is positioned as a leading publicly traded pure-play provider in a fragmented industry, leveraging its size and geographic scale for national marketing, increasing out-of-state referrals, and expanding its service offerings.

The company's core business model involves operating 277 behavioral healthcare facilities with over 12,500 beds in 40 states and Puerto Rico as of December 31, 2025. Revenue is generated from state governments (Medicaid), commercial insurers, the federal government (Medicare), and individual patients. For the year ended December 31, 2025, 57.7% ³⁰ of revenue came from Medicaid, 24.6% ³¹ from commercial payors, 14.3% ³² from Medicare, and 3.4% ³³ from other payors. No single facility accounted for more than 4% ¹⁰ of revenue, and no state or U.S. territory accounted for more than 14% ¹¹ of revenue for the year ended December 31, 2025, indicating a diversified revenue and payor base.

ACHC's product and service lines are categorized into acute inpatient psychiatric facilities, specialty treatment facilities, comprehensive treatment centers (CTCs), and residential treatment centers. Acute inpatient psychiatric facilities accounted for 55% ¹² of total revenue for the year ended December 31, 2025, providing 24-hour observation and intervention for patients with severe psychiatric diagnoses, with typical lengths of stay ranging from three to five days for crisis stabilization and five to twelve days for acute care. Specialty treatment facilities, primarily residential recovery facilities, contributed 17% ¹³ of total revenue, offering a continuum of care for adults with addictive disorders and co-occurring mental disorders, including detoxification, inpatient, partial hospitalization, and outpatient programs.

Comprehensive Treatment Centers (CTCs) generated 17% ¹⁴ of total revenue, specializing in medication-assisted treatment in an outpatient setting for individuals addicted to opiates, combining behavioral therapy and medication. The length of treatment typically lasts longer than one year. Residential treatment centers accounted for 11% ¹⁵ of total revenue, treating patients with behavioral disorders in a non-hospital setting, with lengths of stay ranging from three months to several years, and also include group home and therapeutic group home programs.

For the fiscal year ended December 31, 2025, ACHC reported total revenue of $3,312.8 million ¹⁶, an increase of 5.0% ¹⁷ from $3,154.0 million ¹⁸ in 2024. The company experienced a net loss of $(1,091.9) million ¹⁹, compared to a net income of $264.5 million ²⁰ in 2024. Diluted EPS was $(12.16) ²¹ for 2025, a significant decrease from $2.78 ²² in 2024. Cash and cash equivalents stood at $133.2 million ²³ as of December 31, 2025, compared to $76.3 million ²⁴ in 2024. Total debt (net of debt issuance costs, discounts and premiums) was approximately $2.5 billion ²⁵ at December 31, 2025. The company's operating cash flow was $131.9 million ²⁶ for 2025, compared to $129.7 million ²⁷ for 2024.

Year-over-year, revenue growth was 5.0% ¹⁷ in 2025, compared to 7.7% ³⁴ in 2024. Same facility revenue increased by 4.9% ³⁵ in 2025, driven by a 2.1% ³⁶ increase in patient days and a 2.8% ³⁷ increase in revenue per patient day. Salaries, wages and benefits (SWB) expense increased by $129.7 million ³⁸ to $1,820.7 million ³⁹ in 2025, representing 55.0% ⁴⁰ of revenue, up from 53.6% ⁴¹ in 2024. The company recorded a significant non-cash goodwill impairment charge of $996.2 million ⁴² in 2025, contributing to the net loss.

During the year ended December 31, 2025, ACHC added 1,089 beds ⁴, with 311 beds ⁵ added to existing facilities and 778 beds ⁶ through the opening of one wholly-owned facility and five joint venture facilities. The five joint venture facilities were opened through partnerships with Henry Ford Health, Geisinger Health, Ascension Seton, Fairview Health Services, and ECU Health. Additionally, 15 CTCs ⁷ were opened, and five facilities totaling 382 beds ⁸ were closed. The company also refinanced its Prior Credit Facility with a new Credit Facility, which included a $1.0 billion ⁹ senior secured revolving credit facility and a $650.0 million ²⁸ senior secured term loan facility, both maturing on February 28, 2030. On March 10, 2025, ACHC issued $550.0 million ²⁹ of 7.375% Senior Notes due 2033.

The company's business strategy is to become the indispensable behavioral healthcare provider for the high-acuity and complex needs patient population, committed to providing high-quality, cost-effective behavioral healthcare services, while growing its business, increasing profitability and creating long-term value for its stockholders. This strategy includes five growth pathways: expansions of existing facilities, joint venture partnerships, de novo facilities, acquisitions and expansion across its continuum of care.

A major growth vector for ACHC is the organic expansion of existing facilities, aiming to increase revenue by offering a broader range of services and increasing bed counts. During 2025, 311 beds ⁵ were added to existing facilities. Management believes it can improve efficiencies and increase operating margins by leveraging its expertise within existing programs and improving performance at underperforming facilities, which includes investing in growth in strong markets, addressing capital-constrained facilities, and improving management systems.

Another significant growth area is fueling facility growth through accelerated joint venture partnerships and de novo builds, as well as pursuing programmatic mergers and acquisitions. The behavioral healthcare industry in the U.S. is highly fragmented, and ACHC selectively seeks opportunities to expand and diversify its operations through acquisitions, partnerships with healthcare providers to develop additional facilities, and wholly-owned de novo facilities in attractive markets. In 2025, 778 beds ⁶ were added through the opening of one wholly-owned facility and five joint venture facilities, and 15 CTCs ⁷ were opened. The company has a number of potential acquisitions, joint ventures, and wholly-owned de novo facilities in various stages of development and consideration.

The company also plans to accelerate expansion across the care continuum, particularly for patients with opioid use and other substance use disorders. This growth strategy emphasizes a patient-centric approach covering the full continuum of behavioral healthcare services, aiming to provide cohesive care across sites and levels of care to serve complex patient populations. ACHC is working to reach underserved patient populations by expanding its breadth of services and increasing access points.

Operationally, the company expects to continue navigating a tight labor market, although it notes stability in labor costs and proactive management efforts. Maintenance capital expenditures for the year ended December 31, 2025, amounted to approximately 3% ⁹⁰ of revenue, and the company's maintenance capital expenditure requirements are generally less than other facility-based healthcare providers. The company's IT systems are subject to damage or interruption from various threats, and it must continually evaluate and adapt its systems and processes to address evolving cyber threats.

Regarding capital allocation, for the year ended December 31, 2025, cash paid for capital expenditures was $571.8 million ⁹¹, consisting of routine or maintenance capital expenditures of $104.4 million ⁹² and expansion capital expenditures of $467.4 million ⁹³. The board of directors authorized a share repurchase program on February 25, 2025, allowing the company to acquire up to $300.0 million ⁹⁴ of outstanding common stock. As of December 31, 2025, $250.0 million ⁹⁵ remained under this program.

Management explicitly flagged several structural headwinds and execution risks. The One Big Beautiful Bill Act (OBBBA), passed on July 4, 2025, reduces federal Medicaid expenditures and tightens Medicaid eligibility requirements, including imposing work or community engagement requirements for adults under 65 in Medicaid expansion states and requiring eligibility redeterminations at least every six months by December 31, 2026. These changes could increase financial uncertainty, disrupt ongoing treatment services, complicate eligibility and coverage verification, prior authorization processes, and expose the company to uncompensated care or bad debt. The OBBBA also prohibits states from establishing new provider assessments or taxes, or increasing existing ones, for state fiscal years beginning after October 1, 2026, and caps total payment rates paid by Medicaid managed care organizations for certain services at Medicare payment rates, which impacts Medicaid payment rates for services in hospital facilities. The expiration of enhanced Affordable Care Act (ACA) premium tax credits on December 31, 2025, has led to increased marketplace premiums and a significant reduction in enrollees for the 2026 plan year, potentially increasing uninsured or underinsured patients and uncompensated care.

ACHC faces material risks including governmental investigations, regulatory actions, and whistleblower lawsuits, which can lead to repayment obligations, substantial monetary penalties, corporate integrity agreements, and exclusion from government health programs, as evidenced by the $147.5 million ⁸⁷ legal settlements expense for the 2019 Securities Litigation in 2025 and the $400.0 million ⁸⁸ payment for the Desert Hills Litigation in 2024. The company is also subject to medical malpractice and other lawsuits, with a self-insured retention of up to $10.0 million ⁸⁹ per claim through August 31, 2025, and $15.0 million ⁹⁶ per claim thereafter, and reinsurance coverage limits of $80.0 million ⁹⁷ or $75.0 million ⁹⁸ in aggregate for certain other claims. Compliance with extensive and complex federal, state, and local laws and regulations, including the Anti-Kickback Statute, Stark Law, False Claims Act, and EKRA, is critical, as violations can result in civil and criminal penalties. The OBBBA and the expiration of enhanced ACA premium tax credits on December 31, 2025, are expected to reduce federal Medicaid expenditures, tighten eligibility, and increase marketplace premiums, potentially leading to higher uncompensated care and uncollected patient balances. Operational risks include patient incidents, which can result in regulatory actions, litigation, and negative publicity, and the challenges of integrating acquisitions and developing new facilities, which may involve significant cash expenditures and delays. The company also faces competition for staffing, labor shortages, and higher turnover rates, which may increase labor costs and reduce profitability, and is sensitive to regulatory, economic, environmental, and competitive conditions in Pennsylvania, California, and Tennessee, which collectively represented approximately 31% ⁹⁹ of total revenue in 2025. Cybersecurity incidents pose a continuous threat, potentially leading to substantial sanctions, fines, damages, and reputational harm.

Management's message to shareholders emphasizes a commitment to becoming the indispensable behavioral healthcare provider for high-acuity and complex-needs patient populations, focusing on delivering high-quality, cost-effective services while growing the business, increasing profitability, and creating long-term value. The company's strategic priorities include driving organic growth of existing facilities, fueling facility growth through accelerated joint venture partnerships and de novo builds, pursuing programmatic mergers and acquisitions, and accelerating expansion across the care continuum, particularly for patients with opioid use and other substance use disorders. Management noted that for the year ended December 31, 2025, revenue growth was 5.0% ¹⁷ and that they are navigating a tight labor market with stability in labor costs. They also highlighted the opening of one wholly-owned facility and five joint venture facilities, adding 778 beds ⁶, and 15 CTCs ⁷ during the year. The company's Consolidated Total Net Leverage Ratio was 4.0x ⁸⁶ at December 31, 2025, and they were in compliance with all financial covenants.